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CONCLUSIONS: GMMs have the potential to increase understanding of treatment
effects and identify patients more likely to benefit from treatment. The ability of
baseline characteristics to predict responders/non-responders needs to be tested
prospectively.
Sensory Systems Disorders – Clinical Outcomes Studies
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OCULAR DISCOMFORT, COMPLIANCE AND INTRA-OCULAR PRESSURE (IOP)
CONTROL IN PATIENTS TREATED FOR GLAUCOMA
Lafuma A1, Robert J2, Berdeaux G3
1CEMKA-EVAL, Bourg la Reine, France, 2Cemka Eval, Bourg la Reine, France, 3Alcon France,
Rueil-Malmaison, France
OBJECTIVES: To investigate the associations between ocular discomfort, compli-
ance and efficacy of IOP lowering drugs. METHODS: This was a prospective obser-
vational survey. Centres were selected at random from the CEGEDIM list. Consec-
utive patients treated with an IOP lowering fixed combination drug (prostaglandin
analogues excluded) were included. IOP was collected at two visits (delay fixed by
the investigator). Self-reported compliance measured by validated questionnaires
(EDSQ, TSQM and TEO) and self-reported ocular discomfort (13 items with a focus
at instillation and during the day) based on a questionnaire developed according to
international patient reported outcome recommendations were collected at the
last visit. Patients were classified into 3 groups of compliance (good, minor and
major issues) using the TEO published algorithm. Comparisons between compli-
ance groups were made by ANOVA and chi-square tests. Adjustments were made
for confounding variable unbalances. RESULTS: 410 patients (66 years old, 237
females, 101 ocular hypertensions) were included. 32.9% reported good compli-
ance, 55.9% minor and 11.2% major compliance issues. Patients reporting either red
eyes (P0.02), stinging (P0.007), feeling of sand in the eyes (P0.0009), dry eye
(P0.02), or blurry vision (P0.002) were more likely to report compliance issues.
Patients in the good compliance group reported 3.2 ocular discomfort concerns, 4.5
in the minor and 5.2 in the major compliance issue group (P0.0002). The proba-
bilities to report no concern were 24.2%, 12.7% and 11.9% (P0.02), respectively. An
association between IOP control and compliance was reported in the group of
patients that did not have a change in treatment at the first visit: patients in the
good compliance group had an IOP decrease of 0.9 mmHg, 0.3 mmHg in the minor
and a 0.2 mmHg increase in the major compliance issue group. CONCLUSIONS:
Ocular discomfort issues reported by patients might impact compliance leading to
poor IOP control.
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PREVALENCE, DEMOGRAPHICS AND TREATMENT CHARACTERISTICS OF
VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA IN A
REPRESENTATIVE CANADIAN COHORT
Petrella RJ1, Blouin J2, Davies B2, Barbeau M2
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OBJECTIVES: To determine the prevalence, demographics and treatment charac-
teristics of patients with visual impairment (VI) due to diabetic macular edema
(DME) in a real-world Canadian setting. METHODS: Records from a longitudinal
population-based database of more than 170,000 patients in 53 family practice
clinics in southwestern Ontario, Canada were analyzed between January 1, 2008 to
December 31, 2009. Patient records were limited to those aged 18 years of age and
older. These records contained chart-abstracted information such as visit diagno-
sis, medications and consultation notes. Initial extractions of control, diabetic and
DME patients with VI, defined as best corrected visual acuity20/40 in the DME eye,
were accomplished utilizing International Classification of Disease codes (ICD9/
ICD10); reviewing patient charts for text entries of symptoms that supported a
diagnosis of diabetes and DME and concomitant comorbidity; and reviewing pa-
tient treatment records unique to DME with VI including consultation notes and
hospital discharge summaries. Demographic characteristics, comorbidities, and
treatment were reported. RESULTS: 8368 patients with type 1 or 2 diabetes and a
control cohort of 76,077 patients were extracted for this analysis. Among diabetic
patients, prevalence of DME was 15.7%. Average duration of diabetes among pa-
tients with DME was 19 years. More patients with DME had hypertension (66%), or
vascular disease (28%) than the control cohort (p0.05). The prevalence of VI due to
DME was 2.56%. Mean age was 6417. In patients with VI due to DME, 53% had focal
and 47% had diffuse edema. For both focal and diffuse edema, the most common
treatment was laser monotherapy, used in 62% and 53% of cases, respectively.
CONCLUSIONS: : In a real-world setting, among patients with diabetes, we ob-
served the prevalence of VI due to DME at 2.56% . Laser monotherapy was the most
common treatment.
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INCIDENCE AND CHARACTERISTICS OF PATIENTS WITH MACULAR EDEMA
SECONDARY TO RETINAL VEIN OCCLUSION IN A REPRESENTATIVE CANADIAN
COHORT
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OBJECTIVES: Retinal vein occlusion (RVO) has an abrupt onset and is an important
cause of visual morbidity. Macular edema (ME) is the most common cause of visual
impairment (VI) in patients with RVO. The Canadian incidence of VI due to ME
secondary to RVO is unknown. This study aimed to determine the annual incidence
and characteristics of patients with ME secondary to branch RVO (BRVO) and cen-
tral RVO (CRVO) in a real-world Canadian setting. METHODS: Records from a lon-
gitudinal population-based database of more than 170,000 patients in 53 family
practice clinics in southwestern Ontario, Canada were analyzed between January 1,
2008 and December 31, 2009. These records contained chart-abstracted informa-
tion such as visit diagnosis, medications and consultation notes. Initial extractions
of control cohort and RVO patients with ME and VI (defined as best corrected visual
acuity 20/40 in the RVO eye), were accomplished utilizing International Classifi-
cation of Disease codes (ICD9/ICD10); reviewing patient charts for text entries of
symptoms that supported a diagnosis of RVO and concomitant comorbidity; and
reviewing patient treatment records unique to RVO including consultation notes
and hospital discharge summaries. Demographic characteristics and comorbidi-
ties were reported. RESULTS: Seventy-three (53 with BRVO and 20 with CRVO) of
47,166 patients over 40 years (mean age 6117 years) with new diagnosis of RVO
and a control cohort of 76,077 patients were extracted for this analysis. The annual
incidence of VI due to ME secondary to BRVO and CRVO was 0.056% and 0.021%,
respectively. More RVO patients had hypertension (68 vs. 18%) or dyslipidemia (16
vs. 10%) than control cohort (p0.05). One-quarter of RVO patients had a history of
vascular disease, primarily MI and stroke. CONCLUSIONS: In a real-world setting,
the annual incidence of VI due to ME secondary to BRVO and CRVO was 0.056% and
0.021%, respectively. RVO is associated with several vascular comorbidities.
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LONGER TERM PATIENT BENEFITS OF POLYQUAD® PRESERVATIVE INSTEAD OF
BENZALKONIUM CHLORIDE IN PROSTAGLANDIN EYE DROPS: A
MICROSIMULATION MODEL IN OCULAR HYPERTENSION AND OPEN-ANGLE
GLAUCOMA
Gerlier L1, Lamotte M1, Berdeaux G2, Verboven Y3, Pfeiffer N4
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OBJECTIVES: The presence of the preservative benzalkonium chloride (BAK) at
0.01% concentration in commercialized prostaglandin eye drops for glaucoma is
known to increase the risk of ocular surface disease (OSD), which worsens with the
extent of exposure to BAK. We aimed to estimate longer term clinical outcomes
with travoprost preserved with Polyquad® 0.001% instead of BAK. METHODS: A
Markov microsimulation model was developed (TreeAge) to assess the develop-
ment of OSD and disease progression (Mean Defect [MD], in db) over 10 years, in
patients initiating travoprost with Polyquad® followed by travoprost/beta-blocker
fixed combination vs. the same sequence using BAK-preserved drops. Initial pa-
tient’s characteristics came from distributions on age (normal), sex, OSD presence,
disease stage (uniform) and anticipated progression rates (triangular). The risk of
developing OSD in aging population was derived from a US incidence study, mul-
tiplied by independent risk factors (age, sex, duration and amount of BAK-contain-
ing drops received). Rates of disease progression (db/year) came from landmark
studies in OHT/glaucoma, multiplied by independent accelerating factors (disease
stage, treatment line, OSD severity, non-compliance). Compliance was expected by
experts to be 20% (absolute) better with Polyquad® vs. BAK-preserved drops.
RESULTS: Using 3000 trials (mean age 57 years, 57% female, 14% with initial OSD,
mean MD -4db), 47.6% [41.5-53.6%] of patients receiving in first and second line
BAK-preserved travoprost treatments are expected to have OSD at 10 years versus
31.7% [28.5-35.1%] with Polyquad®. In OHT/early glaucoma patients, the model
predicted the progression to advanced glaucoma (MD-12db) of 13.2% [12.0-14.4%]
with Polyquad® versus 18.1% [16.7-19.5%] with BAK. In patients diagnosed with
moderate glaucoma, 1.9% [1.4-2.4%] versus 5.6% [4.8-6.4%] progressed to blindness
(MD-24db) respectively. CONCLUSIONS: The model estimated that OSD inci-
dence was reduced by 33% and glaucoma disease progression was significantly less
frequent after 10 years of use of Polyquad® versus BAK-containing travoprost eye
drops.
PSS5
VISUAL FIELD EVOLUTION IN GLAUCOMA PATIENTS PRESENTING WITH
DIFFERENT DISEASE STAGES: RESULTS FROM AN OBSERVATIONAL STUDY
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OBJECTIVES: The progression of glaucoma is measured by a Mean Defect (MD) of
the perimetry in decibels (db), from an early disease stage (6db loss), until mod-
erate (6-12db loss), advanced stages (12-24db loss) and eventually blindness (24db
loss). The rate of disease progression is highly variable between individuals and
hard to predict. The objective of this study was to analyze the change in MD of
glaucoma patients in a real-life setting in Germany. METHODS: We analyzed pa-
tient-level data from a German observational study in ocular hypertension (OHT)
and glaucoma, with retrospective collection of MD measures (db). Descriptive sta-
tistics were derived on the rate of disease progression (db loss/year, obtained by
dividing the change in MD by the duration of observation). The change in MD in
best eye between the time of first treatment until last MD measure was included in
a generalized linear regression, adjusting for age, sex, presence of cataract, time
since first treatment, initial MD and initial glaucoma stage (OHT, early/moderate or
advanced). RESULTS: MD data was available for 57 patients (53% female, mean age
67 /12 years). The mean (SD) time from first treatment until last MD measure
was 7.0 (3.7) years. The mean (SD) MD was -4.5db (4.7) at first treatment and -6.0db
(6.8) at last assessment (i.e. average rate of progression of -0.21db/year, all stages).
In 12 OHT patients, 50% had no MD worsening, while 50% lost on average -0.26db/
year. Based on the adjusted analysis, the initial diagnosis was significantly associ-
ated with the amount of db loss over time (early/moderate glaucoma -0.19db/year
/0.13, advanced -0.66db/year /0.22, p0.038). CONCLUSIONS: The rates of
disease progression measured over more than 7 years in glaucoma patients was
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significantly increasing with their initial disease severity. Amount of db loss per
year were in line with previously published prospective studies.
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EPIDEMIOLOGY, DISEASE BURDEN, SYMPTOMATOLOGY, TREATMENT
PATTERN, AND QUALITY OF LIFE IN MACULAR DEGENERATION IN KOREA:
SYSTEMATIC LITERATURE REVIEW BASED ON KOREAN EVIDENCE
Sohn HS
Sookmyung Women’s University, Seoul, South Korea
OBJECTIVES: The objective of this study was to summarize epidemiology, disease
burden, symptomatology, treatment pattern, and quality of life in macular degen-
eration (MD) in the Korean population through a systematic literature review.
METHODS: Literature searches were conducted through Korean databases(RISS,
KMBase, KoreaMed, NDSL, National Assembly Library), national statistics portals
and ophthalmology journals for the period to April 2011, using macular degener-
ation as a keyword. Publications were selected according to pre-defined selection
criteria. RESULTS: Forty-three studies were identified and included in the review.
Most (40) described clinical characteristics and treatment pattern. 4 described ep-
idemiology and 2 focused on quality of life. No study estimated economic burden.
In summary, 1) MD characterizes exudative form, subretinal neovascularization or
retinal pigment epithelial detachment, and equal distribution of circular and geo-
graphic atrophy; 2) MD is a major reason of low vision/visual impairment; 3) Drug
therapy such as bevacizumab or ranibizumab presents effects on decrease of cen-
tral macular thickness and preservation of visual acuity, but optimized patients
have to be identified. Photodynamic therapy is relatively safe, and pneumatic dis-
placement or radiation therapy is somehow effective on visual acuity even though
being a risk of vision loss. Concurrent drug and non-drug therapies have been tried
as well clinically; 4) Prevalence of MD is higher in elderly over 65 years with 13.3%
rate and higher proportion of exudative form than western countries; and 5) Qual-
ity of life is decreased in patients with MD or low vision. CONCLUSIONS: This study
describes lack of local information especially disease burden and quality of life. In
the era growing sharply aging population, prevent and treat MD are crucial for
preserving vision and improving quality of life. Therefore future studies are
needed.
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PREVALENCE ASSESSMENT OF DIABETIC MACULAR EDEMA WITH VISUAL
IMPAIRMENT IN SPAIN: A PREVAIL STUDY
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OBJECTIVES: Diabetic macular edema (DME) is the main cause of visual impair-
ment (VI) in diabetic patients. The prevalence of DME is estimated to be 5.4% in
Europe, but there is no observational evidence currently available. The objective
was to determinate the prevalence of DME and DME with VI from Belgium, France,
Germany, Italy, The Netherlands, Spain and UK, in an epidemiological study. Re-
ported here are the results from Spain. METHODS: Patients with diabetes mellitus
types 1 and 2 (DM1 and DM2) were consecutively recruited by General Practitioners
(GPs) across Spain. Diagnosis and severity of DME, related VI, sociodemographics,
general and ophthalmic comorbidities, HbA1c, antidiabetic and DME treatment
were documented. Patients with retinitis pigmentosa, epiretinal membrane, or
active uveitis were excluded from the calculation of VI due to DME. RESULTS: A
total of 26 GPs recruited 445 eligible patients (38 DM1, 411 DM2) from July 2010 to
April 2011, 51.2% male, mean (SD) age of 66.2 (12.8) years, 37.2% smokers or ex-
smokers. Patients with DME diagnosis showed a longer length of time since onset
of diabetes (14.55 y vs 9.64). The prevalence of DME was estimated to be 4% (18/445
patients) (95%CI 2.2-5.8%) and VI due to DME was 2% (9/445) (95%CI 0.7-3.3%). Poor
diabetic control (HbA1c 7%) was reported in 219 (48.8%) of all patients, being
higher in those with DME (66.7%). Ocular comorbidities, such as cataract or glau-
coma, were present in 17 (94.4%) DME patients. 15 (83.3%) patients received DME
treatment, mainly laser photocoagulation (77.8%), alone or in combination with
vitrectomy and/or pharmacological treatment. CONCLUSIONS: ME affects 4% of
the diabetic patients in Spain, and 2% of them suffer VI due to DME. Results suggest
that poor diabetic control and long time since diabetis onset are associated with
development of DME. This study was sponsored by Novartis Pharma AG.
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ADVANCED CUTANEOUS MELANOMA IN THE UK: A SYSTEMATIC REVIEW
Poku E1, Cooper K1, Wang Q2, Bapat U2, Lebmeier M2
1University of Sheffield, Sheffield, South Yorkshire, UK, 2Bristol-Myers Squibb, Uxbridge,
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OBJECTIVES: Cutaneous malignant melanoma (CMM) is an uncommon yet aggres-
sive form of skin cancer. In 2008, CMM was found to be the sixth most common
cancer in the UK. The aim of this review was to identify the incidence of advanced
CMM in the UK (UK). The definition of advanced CMM was stage IIIc and stage IV
disease in affected patients. METHODS: Multiple sources including the Cochrane
Library, MEDLINE, EMBASE and CINAHL were searched between December 2010
and March 2011. Searches were also conducted by scanning the websites of the
Office of National Statistics, Cancer Research UK as well as the Welsh Cancer In-
telligence and Surveillance Unit. A narrative synthesis was undertaken due to
heterogeneity in included studies. RESULTS: Of the three included studies, 2 were
conducted in Scotland while one was undertaken in the East Anglia region of Eng-
land. Although all patients had a confirmed diagnosis of CMM, variations in staging
methods and unclear or insufficient reporting made it challenging to identify pa-
tients with stage IIIc and stage IV disease. Both studies undertaken in Scotland at
different periods reported that 2% of all melanoma patients had advanced CMM at
the time of diagnosis. However, the definitions of advanced CMM were not similar
in each study. The incidence of stage IV CMM reported in 3,971 patients from East
Anglia decreased from 0.42 to 0.13 per 100,000 population per year between 1991
and 2004.CONCLUSIONS:This review highlighted the lack of, and need for primary
studies to estimate the incidence of advanced CMM in the UK. In order to examine
trends across UK as well as identify patients for targeted treatment, we suggest that
researchers must clearly define this sub-group in future studies.
Sensory Systems Disorders – Cost Studies
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THE BURDEN OF AGE-RELATED MACULAR DEGENERATION IN THE
NETHERLANDS
Boland MRS1, Vingerling J2, Groot M3, Hakkaart-van Roijen L1
1Erasmus University, Rotterdam, The Netherlands, 2Erasmus Medical Center, Rotterdam,
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OBJECTIVES: Age-Related Macular Degeneration (AMD) is a disorder of the central
area of the retina resulting in a significant loss of visual acuity. AMD is the leading
cause of incurable blindness and visual impairment in industrialized countries.
Consequently AMD leads to decrease of Quality of Life (QoL) and increased health
care costs. For the The Netherlands no information on the burden of AMD was
available. The main aim of this study was to assess the burden of AMD patients in
the The Netherlands in terms of health care costs and QoL from a societal
perspective. METHODS: AMD cost parameters were identified and the ‘AMD cost
and impact questionnaire’ was developed. Members of the Dutch Macular Degen-
eration Patient Organization with a disease severity ranging from normal vision to
legally blind were invited to enter the study during regional meetings. The EuroQol
5D was used for measuring QoL. Data on resource use and QoL were collected
through telephone interviews. RESULTS: Seventy-five patients completed the
questionnaire. The average total annual cost for AMD was €5651 per person (95% CI:
4252 - 7051). Home help was the major cost component (€2507 p.p.). Total costs
were significantly higher for individuals with more severe AMD and the QoL sig-
nificantly lower for individuals with more severe AMD (P0.05). The average utility
of AMD was 0.792 (95% CI: 0.771-0.812) significantly lower than the average 50
Dutch population (0.850). The respondents reported ‘usual activities’ as the area
with the most problems. CONCLUSIONS: Increased visual impairment leads to
significantly higher annual costs and lower overall QoL.
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ECONOMIC OUTCOMES OF GLAUCOMA TREATMENT WITH PROSTAGLANDIN
EYE DROPS PRESERVED WITH POLYQUAD® INSTEAD OF BENZALKONIUM
CHLORIDE IN GERMANY
Gerlier L1, Lamotte M1, Lorenz K2, Berdeaux G3, Verboven Y4, Pfeiffer N2
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OBJECTIVES: In glaucoma patients, the long term use of prostaglandin eye drops
containing benzalkonium chloride (BAK) increases the risk of developing an ocular
surface disease (OSD). Polyquad® preserved prostaglandins are now available,
among which travoprost proved similar in efficacy and safety compared to BAK-
preserved formulations. We aimed to estimate the impact of Polyquad® instead of
BAK on glaucoma management cost.METHODS:A Markov microsimulation model
was developed in TreeAge, including 5 health states corresponding to 4 treatment
lines plus death, in representative, treatment-naive patients at different OHT/glau-
coma stages. The sequence travoprost-travoprosttimolol fixed combination pre-
served with Polyquad® was compared to BAK-preserved latanoprost-
latanoprosttimolol (LAT) and bimatoprost-bimatoprosttimolol (BIM). The
model events were: onset of OSD (risk factors: age, sex, BAK exposure; sources: US
incidence study [Moss 2005], Erb 2008), need for treatment change including sur-
gery/laser (risk factors: treatment line, disease stage, OSD presence, BAK exposure;
sources: persistence studies in UK GPRD [Lafuma 2007] and US claims database
[Schmier 2010]), and disease progression (risk factors: treatment line, OSD severity,
non-compliance; sources: large prospective studies in OHT/glaucoma). Costs data
came from a German observational study in OHT/glaucoma with 5-year retrospec-
tive collection of medical resources used (Statutory Health Insurance perspective
patient co-payments; 2011 drug costs, other costs 2010). The 95% confidence inter-
vals came from a probabilistic sensitivity analysis. RESULTS: After 10 years, the
total management cost in the travoprost with Polyquad® arm was €4677 [4378;
5013] compared to €5196 [4904;5482] with LAT and €5342 [5069;5664] with BIM. More
patients required eye surgery/laser procedures with BAK-preserved sequences
(LAT: 4.7% [3.2;6.4%], BIM: 6.0% [4.0;8.3%]) compared to travoprost with Polyquad®
(1.8% [0.9;2.9%]). CONCLUSIONS: At 10 years, prostaglandin treatment with Poly-
quad® is expected to reduce the cost of glaucoma treatment by 10-15% from both
individual and societal perspectives, and have lower surgery/laser rates compared
to BAK-preserved treatments.
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RANIBIZUMAB AND BEVACIZUMAB FOR THE TREATMENT OF AGE-RELATED
MACULAR DEGENERATION: A SYSTEMATIC REVIEW AND ECONOMIC
EVALUATION
Martinez Ferez IM, Flores Moreno S
Andalussian Agency for Health Technology assesment, Sevilla, Spain
OBJECTIVES: To evaluate and comparate the efficacy, safety and cost of the bev-
acizumab and ranibizumab intravitreous injections for the treatment of age related
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